Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:FPRX's Cash-to-Debt is ranked higher than
77% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:FPRX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:FPRX' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.85
NAS:FPRX's Equity-to-Asset is ranked higher than
76% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NAS:FPRX: 0.85 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:FPRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.74 Max: 0.87
Current: 0.85
-2.63
0.87
Interest Coverage No Debt
NAS:FPRX's Interest Coverage is ranked higher than
72% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:FPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:FPRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 4.04
Beneish M-Score: -2.01
WACC vs ROIC
27.62%
500.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -212.82
NAS:FPRX's Operating Margin % is ranked lower than
57% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NAS:FPRX: -212.82 )
Ranked among companies with meaningful Operating Margin % only.
NAS:FPRX' s Operating Margin % Range Over the Past 10 Years
Min: -383.22  Med: -204.36 Max: 75.56
Current: -212.82
-383.22
75.56
Net Margin % -206.02
NAS:FPRX's Net Margin % is ranked lower than
56% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NAS:FPRX: -206.02 )
Ranked among companies with meaningful Net Margin % only.
NAS:FPRX' s Net Margin % Range Over the Past 10 Years
Min: -380.23  Med: -201.98 Max: 65.73
Current: -206.02
-380.23
65.73
ROE % -40.33
NAS:FPRX's ROE % is ranked higher than
51% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:FPRX: -40.33 )
Ranked among companies with meaningful ROE % only.
NAS:FPRX' s ROE % Range Over the Past 10 Years
Min: -52.26  Med: -30.84 Max: 96.31
Current: -40.33
-52.26
96.31
ROA % -33.14
NAS:FPRX's ROA % is ranked higher than
51% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:FPRX: -33.14 )
Ranked among companies with meaningful ROA % only.
NAS:FPRX' s ROA % Range Over the Past 10 Years
Min: -53.75  Med: -31.53 Max: 70.93
Current: -33.14
-53.75
70.93
ROC (Joel Greenblatt) % -509.04
NAS:FPRX's ROC (Joel Greenblatt) % is ranked higher than
50% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:FPRX: -509.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:FPRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1846.49  Med: -702.59 Max: 6887.63
Current: -509.04
-1846.49
6887.63
3-Year Revenue Growth Rate 15.30
NAS:FPRX's 3-Year Revenue Growth Rate is ranked higher than
71% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:FPRX: 15.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:FPRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -70  Med: -23 Max: 20.4
Current: 15.3
-70
20.4
3-Year EBITDA Growth Rate -45.60
NAS:FPRX's 3-Year EBITDA Growth Rate is ranked lower than
86% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:FPRX: -45.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:FPRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -45.6 Max: 21.4
Current: -45.6
0
21.4
3-Year EPS without NRI Growth Rate -44.30
NAS:FPRX's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. NAS:FPRX: -44.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:FPRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 22.4
Current: -44.3
0
22.4
GuruFocus has detected 2 Warning Signs with Five Prime Therapeutics Inc NAS:FPRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:FPRX's 30-Y Financials

Financials (Next Earnings Date: 2018-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

FPRX Guru Trades in Q3 2017

Steven Cohen 62,982 sh (New)
Paul Tudor Jones 10,133 sh (-15.55%)
Jim Simons 70,700 sh (-83.62%)
» More
Q4 2017

FPRX Guru Trades in Q4 2017

Pioneer Investments 202,800 sh (New)
Steven Cohen 201,700 sh (+220.25%)
Paul Tudor Jones 16,496 sh (+62.79%)
Jim Simons Sold Out
» More
Q1 2018

FPRX Guru Trades in Q1 2018

Jim Simons 369,200 sh (New)
Pioneer Investments 202,800 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q2 2018

FPRX Guru Trades in Q2 2018

Pioneer Investments Sold Out
Jim Simons 223,800 sh (-39.38%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:FPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ZIOP, NAS:FATE, NAS:AKAO, NAS:ARWR, NAS:RYTM, XSWX:MOLN, XKRX:031390, NAS:DRNA, ROCO:4157, XKRX:048530, NAS:BYSI, NAS:SRNE, NAS:GLYC, NAS:CASC, ASX:MSB, NAS:PGNX, SZSE:300181, NAS:NCNA, NAS:ACRS, OSTO:PROB » details
Traded in other countries:5P8.Germany,
Headquarter Location:USA
Five Prime Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel protein therapeutics to improve lives of patients with serious diseases.

Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.

Top Ranked Articles about Five Prime Therapeutics Inc

Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek — Fundamental Analysis, Key Performance Indications
Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics — New Research Emphasizes Economic Growth
Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27
Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
Five Prime Therapeutics Announces Closing of Upsized Public Offering
Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
Five Prime Announces Pricing of Upsized Public Offering of Common Stock
Five Prime Announces Proposed Public Offering of Common Stock
Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time

Ratios

vs
industry
vs
history
PB Ratio 1.44
FPRX's PB Ratio is ranked higher than
86% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. FPRX: 1.44 )
Ranked among companies with meaningful PB Ratio only.
FPRX' s PB Ratio Range Over the Past 10 Years
Min: 1.33  Med: 2.96 Max: 8.42
Current: 1.44
1.33
8.42
PS Ratio 7.20
FPRX's PS Ratio is ranked higher than
63% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. FPRX: 7.20 )
Ranked among companies with meaningful PS Ratio only.
FPRX' s PS Ratio Range Over the Past 10 Years
Min: 1  Med: 9.17 Max: 50.54
Current: 7.2
1
50.54
EV-to-EBIT -1.21
FPRX's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. FPRX: -1.21 )
Ranked among companies with meaningful EV-to-EBIT only.
FPRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.8  Med: -3.7 Max: 4.6
Current: -1.21
-13.8
4.6
EV-to-EBITDA -1.21
FPRX's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. FPRX: -1.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
FPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.2  Med: -3.8 Max: 4.5
Current: -1.21
-14.2
4.5
EV-to-Revenue 2.54
FPRX's EV-to-Revenue is ranked higher than
87% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. FPRX: 2.54 )
Ranked among companies with meaningful EV-to-Revenue only.
FPRX' s EV-to-Revenue Range Over the Past 10 Years
Min: -4.9  Med: 9.9 Max: 38.4
Current: 2.54
-4.9
38.4
Current Ratio 12.01
FPRX's Current Ratio is ranked higher than
81% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. FPRX: 12.01 )
Ranked among companies with meaningful Current Ratio only.
FPRX' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 8.38 Max: 12.01
Current: 12.01
1.96
12.01
Quick Ratio 12.01
FPRX's Quick Ratio is ranked higher than
81% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. FPRX: 12.01 )
Ranked among companies with meaningful Quick Ratio only.
FPRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.96  Med: 8.38 Max: 12.01
Current: 12.01
1.96
12.01
Days Sales Outstanding 16.06
FPRX's Days Sales Outstanding is ranked higher than
86% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. FPRX: 16.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
FPRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.9  Med: 7.83 Max: 121.33
Current: 16.06
3.9
121.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.10
FPRX's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. FPRX: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FPRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -176.2  Med: -125 Max: -9.1
Current: -9.1
-176.2
-9.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.68
FPRX's Price-to-Net-Cash is ranked higher than
90% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. FPRX: 1.68 )
Ranked among companies with meaningful Price-to-Net-Cash only.
FPRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.53  Med: 3.53 Max: 7.44
Current: 1.68
1.53
7.44
Price-to-Net-Current-Asset-Value 1.63
FPRX's Price-to-Net-Current-Asset-Value is ranked higher than
90% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. FPRX: 1.63 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
FPRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.48  Med: 3.47 Max: 7.24
Current: 1.63
1.48
7.24
Price-to-Tangible-Book 1.46
FPRX's Price-to-Tangible-Book is ranked higher than
89% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. FPRX: 1.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FPRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.33  Med: 3.27 Max: 6.87
Current: 1.46
1.33
6.87
Price-to-Intrinsic-Value-Projected-FCF 1.59
FPRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. FPRX: 1.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
FPRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.43  Med: 1.76 Max: 1.87
Current: 1.59
1.43
1.87
Price-to-Median-PS-Value 0.78
FPRX's Price-to-Median-PS-Value is ranked higher than
74% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. FPRX: 0.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FPRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.12 Max: 4.68
Current: 0.78
0.16
4.68
Earnings Yield (Greenblatt) % -84.44
FPRX's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. FPRX: -84.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FPRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -134  Med: -15.1 Max: 70.3
Current: -84.44
-134
70.3

More Statistics

Revenue (TTM) (Mil) $61.62
EPS (TTM) $ -4.20
Beta4.08
Volatility47.70%
52-Week Range $12.52 - 47.63
Shares Outstanding (Mil)35.58

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}